Aaron Aday, MD
Cardiovascular Disease · Nashville, TNNPI 1336469220
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,090 of the $19,730 with a category attached, or 71.4%. Merck accounts for 86.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $12,956, more than ten times the $182 reported in 2022. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $580.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$17K
- Tactile Systems Technology Inc$2K
- Novo Nordisk$152
- Janssen Scientific Affairs, LLC$107
- Medtronic$75
- Boston Scientific$24
Across 33 payments — averaging $5430.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$80K
- Novartis$70K
- Aytu Biopharma, Inc.$16K
- Amgen$14K
What the payments were for
- Consulting fees$14,09071%
- Speaking & faculty fees$2,00010%
- Travel & lodging$2,36812%
- Food & beverage$1,2726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 25 | $17,099 |
| Tactile Systems Technology Inc | 3 | $2,275 |
| Novo Nordisk | 3 | $152 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| Medtronic | 1 | $75 |
| Boston Scientific | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flexitouch Plus$2,275
- Nimbl$2,141
- Entre Plus$134
- XARELTO$107
How this compares
$19,730 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $74,174 |
| XareltoRivaroxaban | 61 | $54,017 |
| Repatha SureclickEvolocumab | 23 | $21,523 |
| Atorvastatin Calcium | 87 | $1,361 |
| Ezetimibe | 32 | $804 |
| Rosuvastatin Calcium | 31 | $743 |
| Metoprolol Succinate | 38 | $494 |
| Carvedilol | 26 | $440 |
| Losartan Potassium | 29 | $327 |
| Amlodipine Besylate | 28 | $208 |
| Warfarin Sodium | 16 | $136 |
| ClopidogrelClopidogrel Bisulfate | 15 | $114 |
| Hydrochlorothiazide | 14 | $16 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.